- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Eugene Science (OTCBB: EUSI), a developer and marketer of advanced health supplements and nutraceutical products, today announced that it has retained Investor Relations International (IRI) ( http://www.irintl.com ) to lead an expanded shareholder communications program.
"After years of significant research and development, we believe Eugene Science has reached a pivotal point in its corporate development," said Dr. Seung Kwon Noh, Chief Executive Officer of Eugene Science. "The marketplace for our nutraceutical products and technology is rapidly gaining traction as we begin our transition from a niche market to a mass global market. We believe our investment story now merits the attention of Wall Street and, with the help of IRI, will begin an aggressive investor relations program designed to enhance shareholder value."
As investor relations counsel for Eugene Science, Los Angeles-based IRI will help raise investor awareness of the Company's performance through print and electronic media as well as direct communication with money managers and current or prospective shareholders. The IRI program, focused on the Company's outlook and the execution of its growth strategy, seeks to expand the company's capital resources by broadening the company's shareholder base as well as cementing the long-term loyalty of current shareholders.
To be added to Eugene Science investor e-mail lists, please contact Zachary Bryant at or 818-382-9718.
About Eugene Science
Based in Bucheon, Kyunggi-Do, Korea, Eugene Science is a global biotechnology company tackling ailments such as heart disease, obesity and diabetes through innovation in the nutraceutical field. Its first commercial heart disease product, CZ™, is a patented, nanoscience-based, water-soluble functional food ingredient containing natural plant sterols that help maintain healthy cholesterol levels by inhibiting its absorption. CZ™ is available in capsule form, or as a food or beverage additive. These plant sterols are approved by the U.S. FDA for health claims related to cholesterol lowering efficacy.
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition, from time to time, Eugene Science, or its representatives, have made or may make forward-looking statements, orally or in writing. The words "estimate," "project," "potential," "intended," "expect," "anticipate," "believe" and similar expressions or words are intended to identify forward-looking statements. Such forward-looking statements may be included in, but are not limited to, various filings made by Eugene Science with the United States Securities and Exchange Commission (available at www.sec.gov), press releases or oral statements made with the approval of an authorized executive officer of Eugene Science. Actual results could differ materially from those projected or suggested in any forward-looking statements as a result of a wide variety of factors and conditions. Reference is hereby made to Eugene Science's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 for information regarding those factors and conditions. Among the important factors that could cause actual results to differ materially from management's projections, estimates and expectations include, but are not limited to: changing economic influences in the nutraceutical industry; dependence on key personnel; actions of third parties; the market for nutraceutical products containing Eugene Science's CZ™ ingredient, and availability of adequate financing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only as of the date of this press release. Eugene Science undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
For more information, please click here
Investor Relations International
Copyright © Market WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
New nano approach could cut dose of leading HIV treatment in half February 24th, 2017
PCATDES Starts Field Testing of Photocatalytic Reactors in South East Asia December 28th, 2016